A detailed history of Point72 Hong Kong LTD transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Point72 Hong Kong LTD holds 126 shares of NTLA stock, worth $1,197. This represents 0.0% of its overall portfolio holdings.

Number of Shares
126
Holding current value
$1,197
% of portfolio
0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$19.72 - $27.36 $2,484 - $3,447
126 New
126 $2,000
Q3 2022

Nov 14, 2022

BUY
$53.92 - $71.7 $59,150 - $78,654
1,097 New
1,097 $61,000
Q2 2022

Aug 15, 2022

SELL
$38.49 - $76.21 $87,372 - $172,996
-2,270 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$58.27 - $118.99 $132,272 - $270,107
2,270 New
2,270 $165,000
Q4 2021

Feb 14, 2022

SELL
$100.76 - $138.36 $87,258 - $119,819
-866 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$132.37 - $176.78 $114,632 - $153,091
866 New
866 $116,000
Q4 2020

Feb 16, 2021

SELL
$18.83 - $63.53 $82,305 - $277,689
-4,371 Closed
0 $0
Q3 2020

Nov 16, 2020

BUY
$17.47 - $24.93 $76,361 - $108,969
4,371 New
4,371 $87,000
Q2 2019

Aug 14, 2019

SELL
$13.88 - $18.41 $3,747 - $4,970
-270 Closed
0 $0
Q1 2019

May 15, 2019

BUY
$12.79 - $17.62 $2,468 - $3,400
193 Added 250.65%
270 $5,000
Q4 2018

Feb 14, 2019

SELL
$11.39 - $27.13 $22,848 - $54,422
-2,006 Reduced 96.3%
77 $1,000
Q3 2018

Nov 14, 2018

BUY
$25.78 - $32.6 $47,306 - $59,821
1,835 Added 739.92%
2,083 $60,000
Q2 2018

Aug 14, 2018

SELL
$20.02 - $30.79 $56,396 - $86,735
-2,817 Reduced 91.91%
248 $7,000
Q1 2018

May 15, 2018

BUY
$19.43 - $34.95 $59,552 - $107,121
3,065 New
3,065 $65,000

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $722M
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Point72 Hong Kong LTD Portfolio

Follow Point72 Hong Kong LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Hong Kong LTD, based on Form 13F filings with the SEC.

News

Stay updated on Point72 Hong Kong LTD with notifications on news.